ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,John Allan, MD

Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and odronextamab are shaping treatment algorithms by providing long-term follow-up data that could influence therapeutic strategies and patient management.

Now Viewing

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

Video content above is prompted by the following:

There is a wealth of exciting data emerging from ASH 2024 on bispecific therapies for B-cell lymphomas. Before we discuss these new findings, which bispecific therapies were already available for B-cell lymphomas? How were they typically positioned within treatment algorithms?
Let’s discuss some of the long-term data updates being presented. How do the 3-year follow-up data on epcoritamab in DLBCL impact its role in your treatment algorithms?
4-year follow-up data for mosunetuzumab in follicular lymphoma were also presented. What are the key insights from these data?